Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
LH · NYSE · Healthcare
Fundamental quality
48
out of 100
Labcorp Holdings Inc. earns a fundamental-quality score of 48 out of 100, profiling it as a company with demanding fundamentals. Its score rests mainly on its financial strength (net debt 2.52× EBITDA). Its weakest area is its growth (revenue +0.2%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Labcorp is one of America's two big clinical laboratory networks: blood work and diagnostic tests for millions of patients run through its centers. A volume, routine and scale business where size is the advantage.
EPS growth: -6.3% · Revenue growth: 0.2%
Net margin: 6.7% · ROE: 10.8% · ROIC: 8.1%
Net debt/EBITDA: 2.52x · FCF: 9.8%
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 13,979 | 1,556 | 1,754 | 4,475 |
| 2021 | 13,136 | 2,377 | 2,688 | 3,945 |
| 2022 | 11,864 | 1,279 | 1,527 | 5,020 |
| 2023 | 12,162 | 418 | 874 | 4,518 |
| 2024 | 13,009 | 746 | 1,096 | 4,813 |
| 2025 | 13,952 | 877 | 1,206 | 5,052 |
Between 2020 and 2025, revenue went from $13,979M to $13,952M (+0%) and net income went from $1,556M to $877M (-44%). Meanwhile, its margins have narrowed (from 11% to 6%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the quarter ended March 31, 2026, versus the quarter ended March 31, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$2.88
per share, yearly
27.5% of earnings
Payout
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Labcorp Holdings Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Labcorp Holdings Inc. a good company to invest in?
In terms of business quality, Labcorp Holdings Inc. scores 48 out of 100 in our analysis, placing it as a company with demanding fundamentals. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Labcorp Holdings Inc. a profitable company?
Labcorp Holdings Inc. is profitable, with a net margin of 6.7%, though a thin one.
Does Labcorp Holdings Inc. have a lot of debt?
A moderate level: its net debt is 2.52 times its EBITDA.
Is Labcorp Holdings Inc. growing?
Its revenue has grown 0.2% annualized in recent years.
Does Labcorp Holdings Inc. generate cash?
Yes. It converts about 9.8% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Teva Pharmaceutical Industries (TEVA) · Davita (DVA) · Henry Schein (HSIC) · Brightspring Health Services (BTSG) · Community Health Systems (CYH) · Hims & Hers Health (HIMS) · see more →
The best Healthcare stocks by our model →
Compare Labcorp Holdings Inc. with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Labcorp Holdings Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.